Comparing the construct validity of measurement instruments for pain and stiffness in patients with axial spondyloartwhritis: cross-sectional analysis in the OASIS cohort
The recommended Assessment of SpondyloArthritis international Society Core Outcome Set (ASAS-COS) pain measurement instrument total back pain BASDAI-Q2 has the best known group discrimination. For MS, the ASAS-COS stiffness measure (MS-severity/duration) performs well although MS-severity even slightly better. Known group discrimination is overall stable across CFs.
Authors
- Robert Landewé (ORCID: https://orcid.org/0000-0002-0577-6620)
- Elena Nikiphorou (ORCID: https://orcid.org/0000-0001-6847-3726)
- Robin Christensen (ORCID: https://orcid.org/0000-0002-6600-0631)
- Annelies Boonen (ORCID: https://orcid.org/0000-0003-0682-9533)
- Astrid M van Tubergen (ORCID: https://orcid.org/0000-0001-8477-0683)
- Sofía Ramiro (ORCID: https://orcid.org/0000-0002-8899-9087)
- Dafne Capelusnik (ORCID: https://orcid.org/0000-0001-9336-0416)
- Désirée M F M van der Heijde (ORCID: https://orcid.org/0000-0002-5781-158X)
Institutions
- Tel Aviv Sourasky Medical Center (IL)
- Leiden University Medical Center (NL)
- Maastricht University Medical Centre (NL)
- Odense University Hospital (DK)
- Bispebjerg Hospital (DK)
- Maastricht University (NL)
- King's College Hospital Charity (GB)
- Zuyderland Medisch Centrum (NL)
- Amsterdam University Medical Centers (NL)
Publication Details
- Journal
- RMD Open
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1136/rmdopen-2024-004775
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Oak Foundation
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Parker Institute for Cancer Immunotherapy
- Argenx
- UCB Pharma